PCPhilippe Ceruse

Philippe Ceruse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Ceruse has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Insights From Mutational and Transcriptomic Profiles in Epithelial-myoepithelial Carcinoma

    by Ziyad Alsugair, Françoise Descotes, Anne Champagnac, Jonathan Lopez, Maxime Fieux, Pierre Philouse, Philippe Céruse, Brice Eng Thamphya, Daniel Pissaloux, Franck Tirode, et al.

    Epithelial-myoepithelial carcinoma (EMC) is a rare malignant tumor of the salivary glands, often characterized by HRAS mutations. The present study aimed to better define the molecular and transcriptomic landscape of EMC and explore its relationship with other head and neck neoplasms, particularly basal cell adenoma (BCA). We retrospectively analyzed 14 EMC cases using histology, immunohistochemistry, and whole-exome capture RNA sequencing. HRAS mutations were identified in 57.0% (8/14) of EMC, predominantly at p.Gly61Arg. Additional mutations identified included PIK3CA , STAT5B , and NOTCH1 , as well as gene fusions such as HMGA2 :: WIF1 and FBXO32 :: PLAG1 . A comparative analysis with 54 RAS -mutated head and neck tumors revealed that HRAS mutations were not exclusive to EMC, as they were also found in benign entities such as BCAs. Transcriptomic profiling found that EMC and BCA shared significant gene expression similarities, clustering closely. Differential expression analysis found upregulation of GATA3 , CHI3L1 , GRIA2 , and MME in EMC, while BCAs had enrichment of Wnt-beta-catenin signaling. In contrast, EMCs had activation of the Ras-Raf-MAPK and PI3K-Akt pathways, supported by upregulation of E2F and G2-M checkpoint targets. Immunohistochemistry confirmed GATA3 positivity in HRAS -mutated EMCs. The frequent RAS mutations and overlapping transcriptomic profiles raise important diagnostic considerations and highlight the need for integrated molecular analyses to differentiate these entities. The EMCs displayed a recurrent HRAS mutation, also observed in other head and neck tumors, and were partially clustered with the cases of BCA, suggesting potential biological similarities.


  • Open Access

    Predictive Factors of Malignancy in Cervical Paragangliomas: A Retrospective Study

    by Garance Haw, Maxime Fieux, Anthime Flaus, Hélène Lasolle, Juliette Abeillon, Myriam Decaussin‐Petrucci, Dylan Pavie, Benjamin Verillaud, Philippe Herman, Patrick Feugier, et al.

    Background: Early predictive factors of metastatic cervical paragangliomas (cPG) are lacking. Methods: This multicenter retrospective study included patients with at least one cPG. Metastatic cPG were defined by the histological presence of lymph node metastases or distant metastases. Clinical, radiological, intraoperative, histological, and mutational status characteristics were collected. Predictive factors of metastatic cPG were searched using logistic regression. Results: Sixty‐seven patients were included, corresponding to 86 cPG; 12.8% of these were metastatic. The seven newly identified risk factors were: presence of necrosis (OR = 12.36, 95% CI: [3.03–55.66]), extracapsular extension (OR = 33.42, 95% CI: [2.48–4752.00]), and pathological lymph nodes (OR = 25.00, 95% CI: [3.96–276.07]) on morphological imaging (MRI and/or CT); heterogeneous tumor uptake (OR = 15.5, 95% CI: [2.31–143.68]) and abnormal lymph node uptake (OR = 16.5, 95% CI: [2.04–174.94]) on functional imaging (FDG–PET–CT); invasion of adjacent tissues (OR = 34.63, 95% CI: [3.82–4602.65]) and sacrifice of noble structures (OR = 75.9, 95% CI: [7.99–10230.73]) in patients who underwent surgery. Conclusion: These risk factors could be combined to promptly identify aggressive cPG and adapt therapeutic strategy.

  • Laryngeal graft after total laryngectomy in humans: A SWiM analysis

    by P. Céruse, S. Vergez, J.-P. Marie, B. Baujat, F. Jegoux, O. Malard, S. Albert, L. Badet, J. Blanc, S. Deneuve, et al.


  • 2023: First laryngeal transplantation in France by the “ECLAT” group!

    by P. Céruse, S. Albert, B. Baujat, J. Blanc, C. Fuchsmann, F. Faure, F. Jegoux, J.-P. Marie, O. Malard, E. Morelon, et al.


  • Open Access

    Transoral Laser Microsurgery versus Robot-Assisted Surgery for Squamous Cell Carcinoma of the Tongue Base (Oncological and Functional Results)—A Retrospective GETTEC Multicenter Study

    by Ioana Brudasca, Pierre Philouze, Sylvain Morinière, Benjamin Lallemant, Sébastien Vergez, Olivier Malard, Pierre-Eric Roux, Noémie Rossello, Caroline Payen, Philippe Céruse

    The base of the tongue (BOT) is the second most common site for squamous cell carcinoma (SCC) in the oropharynx. There are currently no clear guidelines for the management of BOT SCC. Our main objective was to compare the oncological outcomes of two minimally invasive approaches, transoral laser microsurgery (TLM) and transoral robot-assisted surgery (TORS). This was a retrospective French GETTEC (Groupe d’Études des Tumeurs de la Tête et du Cou) multicenter study of patients with BOT SCC removed surgically either by TLM or TORS between 2005 and 2021. The study group included 16 patients treated by TLM and 38 by TORS, with median follow-up times of 14.4 and 37.2 months, respectively. The overall survival (OS) rates at 2 and 3 years were 67% in the TLM group and 90% at 2 years and 86% at 3 years in the TORS group (p = 0.42, p = 0.20). There was no significant difference in recurrence-free survival (RFS) between the two techniques after 2 and 3 years. The tumors removed by TORS were significantly larger. Operative times were significantly shorter in the TLM group. There were no differences in feeding resumption; none of the patients in the TLM group required a tracheotomy. Postoperative hemorrhagic complication rates were similar in the two groups (12% for TLM and 13% for TORS). Both TORS and TLM showed encouraging oncological, functional, and safety results in BOT SCC even in recurrence or second primary cancer patients, without a technique being found superior in terms of OS or RFS. Tumors removed by TORS were larger without an increase in postoperative bleeding, extending the possibilities of transoral treatment.


  • Open Access

    A New Animal Model of Laryngeal Transplantation

    by Pierre Philouze, Olivier Malard, Sébastien Albert, Lionel Badet, Bertrand Baujat, Frédéric Faure, Carine Fuchsmann, Franck Jegoux, Jean Lacau-St-Guily, Jean-Paul Marie, et al.

    Only three laryngeal transplants have been described in the literature to date, and none of the techniques has enabled a completely satisfactory functional result to be obtained. This article presents a new model of laryngeal transplantation, with quality of revascularisation of the transplant being the principal objective and optimisation of the various steps of the procedure, with the integration of a new reinnervation technique as a secondary objective. We present a preclinical animal study. Three pig larynges removed in vivo underwent allotransplantation according to the same protocol. The quality of the revascularisation was examined immediately after the surgery as well as by endoscopy for one animal on the fourth day after the operation. The mean time of cold ischaemia was 3 h 15 min. The anaesthetic tolerance of the pigs was excellent. Revascularisation was achieved and judged to be excellent for the three transplants immediately after the operation and the endoscopy performed for one pig on the fourth day after the operation confirmed this result. The anatomical similarities also enabled the application and integration of an innovative technique of laryngeal reinnervation into the various phases of the operation. We describe a reliable and reproducible animal model for laryngeal transplantation. Its application in humans can be envisaged.


  • Open Access

    Circulating Tumor Cell Detection during Neoadjuvant Chemotherapy to Predict Early Response in Locally Advanced Oropharyngeal Cancers: A Prospective Pilot Study

    by Arnaud Gauthier, Pierre Philouze, Alexandra Lauret, Gersende Alphonse, Céline Malesys, Dominique Ardail, Léa Payen, Philippe Céruse, Anne-Sophie Wozny, Claire Rodriguez-Lafrasse

    Patients with locally advanced oropharyngeal carcinoma treated with neoadjuvant chemotherapy are reassessed both radiologically and clinically to adapt their treatment after the first cycle. However, some responders show early tumor progression after adjuvant radiotherapy. This cohort study evaluated circulating tumor cells (CTCs) from a population of locally advanced oropharyngeal carcinoma patients treated with docetaxel, cisplatin, and 5-fluorouracil (DCF) induction chemotherapy or DCF with a modified dose and fractioned administration. The counts and phenotypes of CTCs were assessed at baseline and at day 21 of treatment, after isolation using the RosetteSepTM technique based on negative enrichment. At baseline, 6 out of 21 patients had CTCs (28.6%). On day 21, 5 out of 11 patients had CTCs (41.6%). There was no significant difference in the overall and progression-free survival between patients with or without CTCs at baseline (p = 0.44 and 0.78) or day 21 (p = 0.88 and 0.5). Out of the 11 patients tested at day 21, 4 had a positive variation of CTCs (33%). Patients with a positive variation of CTCs display a lower overall survival. Our findings suggest that the variation in the number of CTCs would be a better guide to the management of treatment, with possible early changes in treatment strategy.


  • Open Access

    CD44, γ-H2AX, and p-ATM Expressions in Short-Term Ex Vivo Culture of Tumour Slices Predict the Treatment Response in Patients with Oral Squamous Cell Carcinoma

    by Pierre Philouze, Arnaud Gauthier, Alexandra Lauret, Céline Malesys, Giovanna Muggiolu, Sylvie Sauvaigo, Antoine Galmiche, Philippe Ceruse, Gersende Alphonse, Anne-Sophie Wozny, et al.

    Squamous cell carcinoma is the most common type of head and neck cancer (HNSCC) with a disease-free survival at 3 years that does not exceed 30%. Biomarkers able to predict clinical outcomes are clearly needed. The purpose of this study was to investigate whether a short-term culture of tumour fragments irradiated ex vivo could anticipate patient responses to chemo- and/or radiotherapies. Biopsies were collected prior to treatment from a cohort of 28 patients with non-operable tumours of the oral cavity or oropharynx, and then cultured ex vivo. Short-term biopsy slice culture is a robust method that keeps cells viable for 7 days. Different biomarkers involved in the stemness status (CD44) or the DNA damage response (pATM and γ-H2AX) were investigated for their potential to predict the treatment response. A higher expression of all these markers was predictive of a poor response to treatment. This allowed the stratification of responder or non-responder patients to treatment. Moreover, the ratio for the expression of the three markers 24 h after 4 Gy irradiation versus 0 Gy was higher in responder than in non-responder patients. Finally, combining these biomarkers greatly improved their predictive potential, especially when the γ-H2AX ratio was associated with the CD44 ratio or the pATM ratio. These results encourage further evaluation of these biomarkers in a larger cohort of patients.


  • History of tonsillectomy and risk of oropharyngeal cancer

    by Jean-Damien Combes, Nicolas Voisin, Sophie Périé, Olivier Malard, Franck Jegoux, Ritoungarte Nadjingar, Guillaume Buiret, Pierre Philouze, Renaud Garrel, Sébastien Vergez, et al.


  • Surgical activity during the Covid-19 pandemic: Results for 112 patients in a French tertiary care center, a quality improvement study

    by P. Philouze, M. Cortet, D. Quattrone, P. Céruse, F. Aubrun, G. Dubernard, J.Y. Mabrut, M.C. Delignette, K. Mohkam

    After the emergence of Covid-19 in China, Hubei Province, the epidemic quickly spread to Europe. France was quickly hit and our institution was one of the first French university to receive patients infected with Sars-COV2. The predicted massive influx of patients motivated the cancellation of all elective surgical procedures planned to free hospitalization beds and to free intensive care beds. Nevertheless, we should properly select patients who will be canceled to avoid life-threatening. The retained surgical indications are surgical emergencies, oncologic surgery, and organ transplantation. We describe the organization of our institution which allows the continuation of these surgical activities while limiting the exposure of our patients to the Sars Cov2. After 4 weeks of implementation of intra-hospital protocols for the control of the Covid-19 epidemic, 112 patients were operated on (104 oncology or emergency surgeries and 8 liver transplants). Only one case of post-operative contamination was observed. No mortality related to Covid-19 was noted. No cases of contamination of surgical care personnel have been reported. We found that the performance of oncological or emergency surgery is possible, safe for both patients and caregivers.